Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NBIX
Strong BuyPremium GrowerAPPROVENeurocrine Biosciences, Inc. · Healthcare · United States · $15.7B · Avg Vol: $196M/d
Neurocrine Biosciences generates strong cash flow from its marketed movement-disorder therapy, runs a net-cash balance sheet and has a strong quality score (Q79) with strong momentum. The small insider selling and marginal consensus trim are immaterial. Nothing adverse is known on accounting, solvency or governance.
COMPANY DESCRIPTION
Neurocrine Biosciences is a neuroscience-focused pharmaceutical company discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company possesses a deep pipeline and commercialized products addressing specific, often underserved, neurological conditions, leveraging proprietary research and development capabilities. Neurocrine is a specialized biopharmaceutical company known for its expertise in neuroscience, focusing on developing first-in-class or best-in-class treatments for central nervous system disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5B | 1.9B | 2.4B | 2.9B | 24.3% | 3.4B | 3.9B | 4.6B | 26.2% |
| EPS | 1.61 | 2.56 | 3.40 | 4.81 | 44.0% | 6.84 | 7.68 | 9.01 | 36.9% |
| Shares | 96.5M | 98.7M | 99.4M | 100.1M | +3.7% | 101.6M | — | — | — |
| Debt | 262.9M | 428.4M | 455.1M | 415.3M | 16.5% | 461.6M | — | — | — |
| Equity | 1.7B | 2.2B | 2.6B | 3.3B | 24.0% | — | — | — | — |
| Op CF | 339.4M | 389.9M | 595.4M | 782.7M | 32.1% | 898.1M | — | — | — |
| Inv CF | -177.1M | -467.1M | -126.8M | -264.4M | — | — | — | — | — |
| Fin CF | -234.3M | 65.3M | -486.7M | -38.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NBIX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NBIX | Neurocrine Biosciences, Inc.(you) | $15.7B | 85 | Strong Buy |
| VTRS | Viatris Inc. | $18.8B | 86 | Strong Buy |
| UTHR | United Therapeutics Corporation | $22.1B | 85 | Strong Buy |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 88 | Strong Buy |
| ELAN | Elanco Animal Health Incorporated | $12.0B | 70 | Buy |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 83 | Strong Buy |
| ZTS | Zoetis Inc. | $32.0B | 66 | Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| LQDA | Liquidia Corporation | $6.1B | 64 | Hold |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%